Search results
Results From The WOW.Com Content Network
On 20 August 2021, India granted emergency authorization to Zydus Cadila's vaccine ZyCoV-D, the world's first DNA plasmid-based COVID-19 vaccine, for patients 12 and older. India granted emergency use approval to the world's first DNA based COVID-19 vaccine, manufactured by for adults and children aged 12 years and above. The vaccine is ...
CoWIN (Covid Vaccine Intelligence Network) is an Indian government web portal for COVID-19 vaccination registration, owned and operated by India's Ministry of Health and Family Welfare. It displays booking slots of COVID-19 vaccine available in the nearby areas and can be booked on the website.
Foreign tourists visiting India contribute significantly to India's economy. [17] People who visit India from countries with different diseases may not have vaccines to protect against infections in India. [17] When tourists do get an infection in India, often that infection could have been prevented with a vaccine. [17] [18]
In February 2020, Cadila Healthcare decided to develop a DNA plasmid based COVID-19 vaccine at their Vaccine Technology Centre (VTC) in Ahmedabad. [6] The vaccine candidate was able to pass the pre-clinical trials on animal models successfully. A report of the study was made available via bioRxiv and later published in the journal Vaccine.
The Centers for Disease Control and Prevention (CDC) currently recommends children from ages 11 to 12 receive two doses of the HPV vaccine, given six to 12 months apart, although children can get ...
In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing an Indian COVID-19 vaccine. [ 25 ] [ 26 ] In June 2020, the company received permission to conduct Phase I and Phase II human trials of a developmental COVID-19 vaccine codenamed BBV152 , from the ...
The first cases of COVID-19 in India were reported on 30 January 2020 in three towns of Kerala, among three Indian medical students who had returned from Wuhan, the epicenter of the pandemic. [10] [11] [12] Lockdowns were announced in Kerala on 23 March, and in the rest of the country on 25 March. Infection rates started to drop in September. [13]
iNCOVACC (codenamed BBV154) [1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [2] [3] American company Precision Virologics [4] [5] and the Washington University School of Medicine in St Louis, Missouri, United States.